
Alicia L. Otton
Examiner (ID: 9618)
| Most Active Art Unit | 1626 |
| Art Unit(s) | 1626, 1699, 4121 |
| Total Applications | 1585 |
| Issued Applications | 975 |
| Pending Applications | 99 |
| Abandoned Applications | 544 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18806791
[patent_doc_number] => 20230381122
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => APPLICATION OF N1-DIHYDROCAFFEOYL-N10-CAFFEOYLSPERMIDINE IN PREPARATION OF DRUG, HEALTH PRODUCT OR FUNCTIONAL FOOD
[patent_app_type] => utility
[patent_app_number] => 18/318192
[patent_app_country] => US
[patent_app_date] => 2023-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4278
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18318192
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/318192 | APPLICATION OF N1-DIHYDROCAFFEOYL-N10-CAFFEOYLSPERMIDINE IN PREPARATION OF DRUG, HEALTH PRODUCT OR FUNCTIONAL FOOD | May 15, 2023 | Pending |
Array
(
[id] => 19096309
[patent_doc_number] => 20240115536
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => DUAL-ACTING PHARMACEUTICAL COMPOSITIONS BASED ON SUPERSTRUCTURES OF ANGIOTENSIN RECEPTOR ANTAGONIST/BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 18/314745
[patent_app_country] => US
[patent_app_date] => 2023-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7738
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18314745
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/314745 | DUAL-ACTING PHARMACEUTICAL COMPOSITIONS BASED ON SUPERSTRUCTURES OF ANGIOTENSIN RECEPTOR ANTAGONIST/BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | May 8, 2023 | Pending |
Array
(
[id] => 18753921
[patent_doc_number] => 20230357266
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/312418
[patent_app_country] => US
[patent_app_date] => 2023-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12111
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312418
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/312418 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | May 3, 2023 | Pending |
Array
(
[id] => 18806824
[patent_doc_number] => 20230381157
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => RIFABUTIN FOR THE TREATMENT OF ACINETOBACTER BAUMANNII
[patent_app_type] => utility
[patent_app_number] => 18/137151
[patent_app_country] => US
[patent_app_date] => 2023-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15677
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18137151
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/137151 | RIFABUTIN FOR THE TREATMENT OF ACINETOBACTER BAUMANNII | Apr 19, 2023 | Pending |
Array
(
[id] => 18522935
[patent_doc_number] => 20230233585
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => USE OF NERIDRONIC ACID OR OF ITS SALT FOR THE TREATMENT OF OSTEOARTHROSIS
[patent_app_type] => utility
[patent_app_number] => 18/192094
[patent_app_country] => US
[patent_app_date] => 2023-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6763
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18192094
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/192094 | USE OF NERIDRONIC ACID OR OF ITS SALT FOR THE TREATMENT OF OSTEOARTHROSIS | Mar 28, 2023 | Pending |
Array
(
[id] => 18522935
[patent_doc_number] => 20230233585
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => USE OF NERIDRONIC ACID OR OF ITS SALT FOR THE TREATMENT OF OSTEOARTHROSIS
[patent_app_type] => utility
[patent_app_number] => 18/192094
[patent_app_country] => US
[patent_app_date] => 2023-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6763
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18192094
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/192094 | USE OF NERIDRONIC ACID OR OF ITS SALT FOR THE TREATMENT OF OSTEOARTHROSIS | Mar 28, 2023 | Pending |
Array
(
[id] => 18970347
[patent_doc_number] => 20240050439
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES
[patent_app_type] => utility
[patent_app_number] => 18/181046
[patent_app_country] => US
[patent_app_date] => 2023-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10178
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18181046
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/181046 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | Mar 8, 2023 | Abandoned |
Array
(
[id] => 18466944
[patent_doc_number] => 20230201224
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/176571
[patent_app_country] => US
[patent_app_date] => 2023-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9629
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18176571
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/176571 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | Feb 28, 2023 | Abandoned |
Array
(
[id] => 20302390
[patent_doc_number] => 12448368
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-21
[patent_title] => Indole compounds as androgen receptor modulators
[patent_app_type] => utility
[patent_app_number] => 18/172690
[patent_app_country] => US
[patent_app_date] => 2023-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 103004
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 367
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18172690
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/172690 | Indole compounds as androgen receptor modulators | Feb 21, 2023 | Issued |
Array
(
[id] => 20302390
[patent_doc_number] => 12448368
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-21
[patent_title] => Indole compounds as androgen receptor modulators
[patent_app_type] => utility
[patent_app_number] => 18/172690
[patent_app_country] => US
[patent_app_date] => 2023-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 103004
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 367
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18172690
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/172690 | Indole compounds as androgen receptor modulators | Feb 21, 2023 | Issued |
Array
(
[id] => 18674986
[patent_doc_number] => 20230312511
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE
[patent_app_type] => utility
[patent_app_number] => 18/111241
[patent_app_country] => US
[patent_app_date] => 2023-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11134
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18111241
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/111241 | Selective D3 dopamine receptor agonists and methods of their use | Feb 16, 2023 | Issued |
Array
(
[id] => 18612287
[patent_doc_number] => 20230279019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => BENZONORBORNADIENE DERIVATIVES AND REACTIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/158356
[patent_app_country] => US
[patent_app_date] => 2023-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23846
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158356
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/158356 | BENZONORBORNADIENE DERIVATIVES AND REACTIONS THEREOF | Jan 22, 2023 | Abandoned |
Array
(
[id] => 18391253
[patent_doc_number] => 20230159471
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => PYRAZINOIC ACID CONJUGATES AND HYBRID CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 18/156316
[patent_app_country] => US
[patent_app_date] => 2023-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8429
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156316
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/156316 | PYRAZINOIC ACID CONJUGATES AND HYBRID CONJUGATES | Jan 17, 2023 | Abandoned |
Array
(
[id] => 18610776
[patent_doc_number] => 20230277506
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => NOVEL PREPARATION CONTAINING BENZIMIDAZOLE DERIVATIVE
[patent_app_type] => utility
[patent_app_number] => 18/095971
[patent_app_country] => US
[patent_app_date] => 2023-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4560
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18095971
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/095971 | NOVEL PREPARATION CONTAINING BENZIMIDAZOLE DERIVATIVE | Jan 10, 2023 | Pending |
Array
(
[id] => 19738271
[patent_doc_number] => 12215089
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-02-04
[patent_title] => Energetic compound embodiments and methods of making and using the same
[patent_app_type] => utility
[patent_app_number] => 18/081409
[patent_app_country] => US
[patent_app_date] => 2022-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 14
[patent_no_of_words] => 7483
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18081409
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/081409 | Energetic compound embodiments and methods of making and using the same | Dec 13, 2022 | Issued |
Array
(
[id] => 18319527
[patent_doc_number] => 20230117655
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => POLYMERIZABLE FUSED TRICYCLIC COMPOUNDS AS ABSORBERS OF UV AND VISIBLE LIGHT
[patent_app_type] => utility
[patent_app_number] => 18/065237
[patent_app_country] => US
[patent_app_date] => 2022-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18917
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18065237
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/065237 | POLYMERIZABLE FUSED TRICYCLIC COMPOUNDS AS ABSORBERS OF UV AND VISIBLE LIGHT | Dec 12, 2022 | Pending |
Array
(
[id] => 18319527
[patent_doc_number] => 20230117655
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => POLYMERIZABLE FUSED TRICYCLIC COMPOUNDS AS ABSORBERS OF UV AND VISIBLE LIGHT
[patent_app_type] => utility
[patent_app_number] => 18/065237
[patent_app_country] => US
[patent_app_date] => 2022-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18917
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18065237
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/065237 | POLYMERIZABLE FUSED TRICYCLIC COMPOUNDS AS ABSORBERS OF UV AND VISIBLE LIGHT | Dec 12, 2022 | Pending |
Array
(
[id] => 19578734
[patent_doc_number] => 12144816
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-19
[patent_title] => Substituted indole Mcl-1 inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/064206
[patent_app_country] => US
[patent_app_date] => 2022-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 101303
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18064206
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/064206 | Substituted indole Mcl-1 inhibitors | Dec 8, 2022 | Issued |
Array
(
[id] => 19250189
[patent_doc_number] => 20240201177
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => FLUORESCENT COMPOUND FOR IMMUNOHISCHEMISTRY AND DIAGNOSIS COMPOSITION FOR DETECTING BIOLOGICAL MATERIAL COMPRISING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/073644
[patent_app_country] => US
[patent_app_date] => 2022-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7094
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 342
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18073644
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/073644 | FLUORESCENT COMPOUND FOR IMMUNOHISCHEMISTRY AND DIAGNOSIS COMPOSITION FOR DETECTING BIOLOGICAL MATERIAL COMPRISING THE SAME | Dec 1, 2022 | Pending |
Array
(
[id] => 18649370
[patent_doc_number] => 20230295169
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/072501
[patent_app_country] => US
[patent_app_date] => 2022-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 85956
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18072501
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/072501 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | Nov 29, 2022 | Issued |